Russell Investments Group
UBX

Russell Investments Group’s Unity Biotechnology UBX Stock Holding History

Russell Investments Group’s Portfolio UBX Stock Details UBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-3,471
Closed -$103K – 3112
2021
Q3 		$103K Sell
3,471
-6,970
-67% -$246K ﹤0.01% 2885
2021
Q2 		$481K Sell
10,441
-8,067
-44% -$388K ﹤0.01% 2607
2021
Q1 		$1.11M Sell
18,508
-7,983
-30% -$544K ﹤0.01% 2204
2020
Q4 		$1.39M Buy
26,491
+6,928
+35% +$334K ﹤0.01% 1951
2020
Q3 		$675K Sell
19,563
-2,042
-9% -$129K ﹤0.01% 2253
2020
Q2 		$1.88M Sell
21,605
-654
-3% -$48.5K ﹤0.01% 1680
2020
Q1 		$1.29M Buy
22,259
+14,843
+200% +$935K ﹤0.01% 1716
2019
Q4 		$534K Buy
7,416
+4,500
+154% +$317K ﹤0.01% 2370
2019
Q3 		$178K Buy
+2,916
New +$206K ﹤0.01% 2641
2019
Q1 		– Sell
-1,378
Closed -$226K – 3013
2018
Q4 		$226K Buy
+1,378
New +$183K ﹤0.01% 2570

Other funds holding UBX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IFA
Invus Financial Advisors New York $89.2M AUM 10.79% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Russell Investments Group's UBX Position: Q4 2021 in Review

Russell Investments Group sold out of Unity Biotechnology (UBX) in Q4 2021, closing a stake of 3,471 shares — an estimated $103K sold.

Russell Investments Group first reported a position in UBX in Q4 2018 and held it in 10 quarters. The position peaked at $1.88M in Q2 2020. 71 funds tracked by Wall St. Rank hold UBX as of Q4 2021.

  • Russell Investments Group reported no remaining Unity Biotechnology position as of Q4 2021 after selling out during the quarter.
  • Russell Investments Group sold 3,471 Unity Biotechnology shares in Q4 2021, an estimated $103K.
  • Russell Investments Group first reported a position in Unity Biotechnology in Q4 2018 and held it in 10 quarters.
  • Russell Investments Group's Unity Biotechnology position peaked at $1.88M in Q2 2020.
  • 71 funds tracked by Wall St. Rank held Unity Biotechnology as of Q4 2021.

Based on Russell Investments Group's 13F filing for Q4 2021, filed 21 Jan 2022.